Bologna

• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Inves … Ended
  2024-512967-29-00 4 2019-09-03 Hypoparathyroidism (HP) in Adults
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended
  2024-515929-28-00 4 2019-08-02 Non-small Cell Lung Cancer
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 5 2019-06-12 Multiple myeloma (MM) with at least 2 prior therapies including an imm
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumo … Ended
  2024-519176-95-00 4 2019-05-08 Gastrointestinal Stromal Tumors (GIST)
• MK-4280 and Pembrolizumab in Hematologic Malignancies Ended
  2023-503587-17-00 9 2019-03-20 Hematologic malignancies
• Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. Ended
  2023-507777-18-00 4 2019-03-19 Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
• A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended
  2023-508655-39-00 7 2019-02-13 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
• Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended
  2023-508127-13-00 4 2019-01-25 Adult patients with refractory or relapsed follicular lymphoma
• A study of full treatment-free remission in patients with chronic myeloid leukemia Ended
  2024-516122-66-00 4 2019-01-18 Chronic myeloid leukemia
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended
  2022-502938-30-00 5 2018-12-10 Moderate and Severe Atopic Dermatitis
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 4 2018-09-03 Mantle Cell Lymphoma
• A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended
  2023-509975-17-00 4 2018-04-12 Relapsed/Refractory Follicular Lymphoma
• Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers. Ended
  2024-516679-33-00 7 2017-12-01 Advanced Solid Tumors and Lymphomas that are metastatic or unresectabl
• A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) o … Ended
  2023-507143-11-00 5 2017-11-08 Precancerous form of blood cancer in the bone marrow
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor … Ended
  2022-500400-22-00 5 2016-06-23 Hodgkin lymphoma
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended
  2024-514515-10-00 5 2016-06-16 Breast Cancer
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC

Showing 841–864 of 875 trials